{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:49Z","timestamp":1791915889906,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020975","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients\u2019 physical and mental wellbeing. The HS Quality of Life questionnaire (HiSQOL\u00a9) was developed to assess HS-specific changes in health-related quality of life (HRQoL), one of the six domains of the core outcome set, established by the HS Core Outcomes Set International Collaboration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the psychometric properties of HiSQOL total and domain scores and determine interpretation thresholds to guide score interpretation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Blinded, pooled data from two bimekizumab phase III trials (BE HEARD I &amp; II) in adult patients with moderate-to-severe HS were used to conduct a confirmatory factor analysis (CFA) and to assess convergent validity [correlations with other patient-reported outcomes (PROs)], known-groups validity [grouping patients according to Hurley stage, International Hidradenitis Suppurativa Severity Score System (IHS4) and patient global impression of HS severity scale], reliability [Cronbach\u2019s \u03b1 and intraclass correlation coefficients (ICCs)] and responsiveness (sensitivity to change). Clinically meaningful within-patient improvement thresholds were estimated by anchor- and distribution-based analyses. Symptom\/impact severity thresholds were estimated by receiver operating characteristic curve analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The CFA models supported the relevance of the three subscales and an underlying unidimensional concept, validating the total score derivation from all items. HiSQOL subscale and total scores showed good convergent and known-groups validity, with HiSQOL scores being consistently higher (worse HRQoL outcomes) for patients with higher disease severity. HiSQOL demonstrated good internal consistency (Cronbach\u2019s \u03b1 \u2265 0.81 for all scores) and test\u2013retest reliability (ICC 0.73\u20130.83 across HiSQOL scores). Correlation coefficients between changes in HiSQOL scores and changes in other PRO scores were all positive and statistically significant (P-values &amp;lt; 0.001), with most exceeding 0.30, demonstrating acceptable responsiveness. Clinically meaningful within-patient improvement thresholds were estimated as: 20\u201321-point decrease for HiSQOL total score (total possible range 0\u201368), 5\u20136-point decrease for symptoms (range 0\u201316), 4\u20135-point decrease for psychosocial (range 0\u201320) and 10\u201311-point decrease for activities\u2013adaptations (range 0\u201332). Thresholds for different levels of symptom\/impact severity were derived.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The HiSQOL subscale and total scores demonstrated robust psychometric properties, supporting the use of HiSQOL to interpret trial results and inform treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf067","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T10:59:29Z","timestamp":1743591569000},"page":"93-104","source":"Crossref","is-referenced-by-count":9,"title":["Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL\u00a9) questionnaire using pooled data from the phase III BE HEARD I &amp; II trials of bimekizumab in hidradenitis suppurativa"],"prefix":"10.1093","volume":"193","author":[{"given":"Joslyn S","family":"Kirby","sequence":"first","affiliation":[{"name":"Department of Dermatology, Penn State University , Hershey, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-9607","authenticated-orcid":false,"given":"Linnea","family":"Thorlacius","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark; Health Sciences Faculty, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[{"name":"UCB Pharma , Colombes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Ciaravino","sequence":"additional","affiliation":[{"name":"UCB Pharma , Colombes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rolleri","sequence":"additional","affiliation":[{"name":"UCB Pharma , Morrisville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pansar","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Muller","sequence":"additional","affiliation":[{"name":"UCB Pharma , Slough ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G","family":"Pelligra","sequence":"additional","affiliation":[{"name":"Evidera , Atlanta , GA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025081313270494400_ljaf067-B1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025081313270494400_ljaf067-B2","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/bjd.16603","article-title":"Profound consequences of hidradenitis suppurativa: a review","volume":"183","author":"Matusiak","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025081313270494400_ljaf067-B3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025081313270494400_ljaf067-B4","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaad.2020.05.090","article-title":"New-onset depression among children, adolescents, and adults with hidradenitis suppurativa","volume":"83","author":"Wright","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025081313270494400_ljaf067-B5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaad.2021.06.843","article-title":"Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa","volume":"86","author":"Wright","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"2025081313270494400_ljaf067-B6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/exd.14123","article-title":"Endpoints of clinical trials for hidradenitis suppurativa: proceedings of a round-table session","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"key":"2025081313270494400_ljaf067-B7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025081313270494400_ljaf067-B8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025081313270494400_ljaf067-B9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000496234","article-title":"Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument","volume":"5","author":"Thorlacius","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"2025081313270494400_ljaf067-B10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"2025081313270494400_ljaf067-B11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025081313270494400_ljaf067-B12","article-title":"Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders","author":"US Food and Drug Administration"},{"key":"2025081313270494400_ljaf067-B13","author":"US Food and Drug Administration"},{"key":"2025081313270494400_ljaf067-B14","author":"US Food and Drug Administration"},{"key":"2025081313270494400_ljaf067-B15"},{"key":"2025081313270494400_ljaf067-B16"},{"key":"2025081313270494400_ljaf067-B17","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"2025081313270494400_ljaf067-B18","first-page":"729","volume-title":"Dermatologic Surgery","author":"Hurley","year":"1989"},{"key":"2025081313270494400_ljaf067-B19","volume-title":"Patient-Reported Outcomes: Measurement, implementation and interpretation","author":"Cappelleri","year":"2014"},{"key":"2025081313270494400_ljaf067-B20","volume-title":"Structural Equation Modeling with EQS: Basic concepts, applications, and programming","author":"Bryne","year":"2006","edition":"2nd edn"},{"key":"2025081313270494400_ljaf067-B21","volume-title":"A Step-by-Step Approach to Using SAS for Univariate & Multivariate Statistics","author":"O\u2019Rourke","year":"2005"},{"key":"2025081313270494400_ljaf067-B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa","volume":"21","author":"Patel","year":"2017","journal-title":"Curr Pain Headache Rep"},{"key":"2025081313270494400_ljaf067-B23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11136-009-9464-4","article-title":"Having a fit: impact of number of items and distribution of data on traditional criteria for assessing IRT\u2019s unidimensionality assumption","volume":"18","author":"Cook","year":"2009","journal-title":"Quality Life Res"},{"key":"2025081313270494400_ljaf067-B24","author":"Hinkle","year":"2003","journal-title":"Applied Statistics for the Behavioral Sciences"},{"key":"2025081313270494400_ljaf067-B25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1015291021312","article-title":"Assessing health status and quality-of-life instruments: attributes and review criteria","volume":"11","author":"Aaronson","year":"2002","journal-title":"Qual of life Res"},{"key":"2025081313270494400_ljaf067-B26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1081\/COPD-200050663","article-title":"Approaches and recommendations for estimating minimally important differences for health-related quality of life measures","volume":"2","author":"Hays","year":"2005","journal-title":"COPD: J Chronic Obstruct Pulmonary Dis"},{"key":"2025081313270494400_ljaf067-B27","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000","edition":"2nd edn"},{"key":"2025081313270494400_ljaf067-B28","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2025081313270494400_ljaf067-B29","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","article-title":"Patient-reported outcome measures as\u00a0complementary information to clinician-reported outcome measures in patients with psoriasis","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025081313270494400_ljaf067-B30","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.3390\/ijerph19053140","article-title":"Associations between patient-reported and clinician-reported outcome measures in patients after traumatic injuries of the lower limb","volume":"19","author":"Bily","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025081313270494400_ljaf067-B31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamadermatol.2023.2008","article-title":"Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling","volume":"159","author":"Long","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025081313270494400_ljaf067-B32","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","article-title":"Comparison between patient-reported and clinician-observed symptoms in oncology","volume":"36","author":"Xiao","year":"2013","journal-title":"Cancer Nurs"},{"key":"2025081313270494400_ljaf067-B33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status: ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"2025081313270494400_ljaf067-B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"2025081313270494400_ljaf067-B35","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamadermatol.2023.3282","article-title":"Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice: a HiSTORIC consensus statement","volume":"159","author":"Mastacouris","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf067\/62842909\/ljaf067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/1\/93\/62842909\/ljaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/1\/93\/62842909\/ljaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T17:27:17Z","timestamp":1755106037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/1\/93\/8103950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf067","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,4,2]]}}}